Horizon Discovery to Collaborate with Novartis | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery and Novartis have struck a collaboration for cancer models that will be used in Novartis' drug research programs.

Cambridge, UK-based Horizon Discovery said this week that under the four-year strategic collaboration it will use its Genesis gene engineering platform to develop a panel of genetically defined mutant and normal (X-MAN) cancer models for the drug company. In return, Novartis will pay Horizon up-front, milestone, and renewal fees of undisclosed value.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.